



1700 1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

In re Application of: :  
Kaesemeyer : Confirmation No. 6530  
Serial No: 10/763,309 : Group Art Unit: 1614  
Filed: January 23, 2004 : Examiner: Dwayne C. Jones

For: PHARMACEUTICAL COMPOSITION COMPRISING CITRULLINE

Date Mailed: March 24, 2006

I HEREBY CERTIFY THAT THIS SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.8 AND IS ADDRESSED TO MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

Kathleen Pujol  
(Typed or printed name of person mailing paper or fee)

\_\_\_\_\_  
(Signature of person mailing paper or fee)

Documents Mailed:  
Information Disclosure Statement (2 pages)  
Form PTO-1449 (1 page)  
Cited References: (9)  
Certificate of Mailing  
Postcard

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kaesemeyer

Serial No. 10/763,309

Filed: January 23, 2004



:

:

:

:

Confirmation No.: 6530

Group Art Unit: 1614

Examiner: Dwayne C. Jones


For: PHARMACEUTICAL COMPOSITION COMPRISING CITRULLINE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.



Substitution Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	10/763,309
<b>Filing Date</b>	January 23, 2004
<b>First Named Inventor</b>	Kaesemeyer
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	Dwayne C. Jones
<b>Attorney Docket Number</b>	126625.801

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code (if known)				
	AA	4,259,314		Lowey	03-31-1981		
	AB	5,451,409		Rencher et al.	09-19-1995		
	AC	4,369,172		Schor et al.	01-18-1983		
	AD	4,389,393		Schor et al.	06-21-1983		
	AE	4,983,396		Bodor et al.	01-08-1991		
	AF	5,543,430		Kaesemeyer	08-06-1996		
	AG	5,767,160		Kaesemeyer	06-16-1998		
	AH	5,968,983		Kaesemeyer	10-19-1999		
	AI	4,857,522		DiPietro et al.	08-15-1989		
	AJ	5,190,970		Pan et al.	03-02-1993		
	AK	5,461,039		Tschollar et al.	10-24-1995		
	AL	5,316,765		Folkers et al.	05-31-1994		
	AM	6,147,109		Liao et al.	11-14-2000		
	AN	6,239,172		Kaesemeyer	05-29-2001		

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			T
		Office	Number	Kind Code (if known)						
	BA		WO 9844893		Kaesemeyer	10-15-1998				
	BB		WO 0056403		Brigham & Women's Hospital	09-28-2000				

**OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.	T
	CA	ROBINSON, Sustained Action Dosage Forms in The Theory and Practice of Industrial Pharmacy 2 <sup>nd</sup> ed., Lachman et al eds., Ch. 14:439-465, 1976	
	CB	IGNARRO, Pharmacology of Endothelium-Derived Nitric Oxide and Nitrovasodilators, 1991, The Western Journal of Medicine, pp. 51-62	
	CC	FEELISCH et al., Biotransformation of Organic Nitrates to Nitric Oxide by Vascular Smooth Muscle and Endothelial Cells, 1991, Biochem. and Biophys. Res. Comm. 180(1):286-293	
	CD	SUNDERKOTTER et al., Macrophages and angiogenesis, 1994, J. Leukoc. Biol. Mar. 55(3):410-422	
	CE	Remington's Pharmaceutical Sciences, 1990, 18 <sup>th</sup> ed., Gennaro ed., Mack Publishing, Easton, PA (TOC)	
	CF	Handbook of Pharmaceutical Excipients, Boylan et al. eds., 1986 (TOC)	
	CG	Pharmaceutical Dosage Forms: Tablets, 2 <sup>nd</sup> ed., Lieberman et al. eds., 1990 (TOC)	

Examiner Signature	Date Considered
-----------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to Deposit Account No. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP



Raymond A. Miller  
Registration No. 42,891

Pepper Hamilton LLP  
One Mellon Bank Center  
50<sup>th</sup> Floor  
500 Grant Street  
Pittsburgh, PA 15219  
Telephone: (412) 454-5813  
Facsimile: (412) 281-0717  
Date: March 24, 2006